REG - Hikma Pharmaceutical - Total Voting Rights

Hikma PharmaceuticalsAnnouncement

01/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231201:nRSA2556Va&default-theme=true

RNS Number : 2556V  Hikma Pharmaceuticals Plc  01 December 2023

 

Hikma Pharmaceuticals PLC

(the Company)

Total Voting Rights and Capital

 

LONDON, 1 December 2023 - In accordance with section 5.6.1 of the UK Financial
Conduct Authority's Disclosure Guidance and Transparency Rules (the 'Rules'),
Hikma Pharmaceuticals PLC

(LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market
of the following:

 

As at 30 November 2023, the issued share capital of the Company comprised of
221,080,093 Ordinary Shares of 10 pence each ('Shares') with voting rights.
This figure excludes 12,833,233 Shares held in treasury, which do not have
voting rights.

 

The figure of 221,080,093 may be used by shareholders (and others with
notification obligations) as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change to their interest in, the Company under the Rules.

 

 

 

- ENDS -

 

Enquiries

 

 Hikma Pharmaceuticals PLC

 Helen Middlemist           +44 20 7399 2760

 Deputy Company Secretary

 

 

About Hikma

Hikma helps put better health within reach every day for millions of people
around the world. For more than 40 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
the United States (US), the Middle East and North Africa (MENA) and Europe,
and we use our unique insight and expertise to transform cutting-edge science
into innovative solutions that transform people's lives. We're committed to
our customers and the people they care for, and by thinking creatively and
acting practically, we provide them with a broad range of branded and
non-branded generic medicines. Together, our 8,700 colleagues are helping to
shape a healthier world that enriches all our communities. We are a leading
licensing partner, and through our venture capital arm, are helping bring
innovative health technologies to people around the world. For more
information, please visit: www.hikma.com
(https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2531421-1%26h%3D3823969217%26u%3Dhttp%253A%252F%252Fwww.hikma.com%252F%26a%3Dwww.hikma.com&data=02%7C01%7Cmellisa%40hikma.uk.com%7C997d2fa3727b41845d4308d7ecef5a5f%7C178c1a723d3c40afbaa754615303bcdc%7C0%7C0%7C637238385059390461&sdata=JoY1dcOqWcUS12nfDFqq49wlYgBsw3%2BZFmrlDQ4QNI0%3D&reserved=0)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREAAFEDDXDFFA